Physician profile
Brandon A Smith
NPI 1497998223
$2,290.06
in general payments reported to CMS, 2019-2025
32 companies · $677 in 2025
The $677 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2020: $63.28 · 2022: $261 · 2023: $530 · 2024: $560 · 2025: $677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,767.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $344.98 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $314.58 | 2023-2025 | |
| Lilly USA, LLC | $228.40 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $192.60 | 2023-2025 | Vraylar, Ubrelvy, Qulipta |
| Sanofi-Aventis U.S. LLC | $190.94 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $126.73 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $117.13 | 2019-2024 | Otezla, Repatha |
| Abbott Laboratories | $101.56 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2, Eterna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.99 | 2020-2024 | Jardiance, Ofev |
| Astellas Pharma US INC | $70.68 | 2025 | Veozah |
| Sumitomo Pharma America, INC. | $44.15 | 2023-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.99 | 2022-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $41.30 | 2024-2025 | Shingrix, Trelegy Ellipta |
| Shield Therapeutics INC | $40.22 | 2022-2023 | Accrufer |
| Medtronic, INC. | $35.39 | 2023-2025 | Kyphon Express II Kyphopak Tray, Inceptiv |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $29.24 | 2025 | Unithroid |
| Medtronic USA, INC. | $27.96 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $24.72 | 2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $22.25 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.98 | 2024 | Caplyta |
| Inspire Medical Systems, INC. | $20.44 | 2024 | Inspire |
| Phathom Pharmaceuticals, INC. | $19.45 | 2024 | Voquezna |
| Xeris Pharmaceuticals, INC. | $18.27 | 2023 | Gvoke Hypopen |
| Corcept Therapeutics | $17.81 | 2025 | Korlym |
| Biohaven Pharmaceutical Holding Company LTD. | $17.10 | 2022 | |
| Sanofi Pasteur INC. | $16.08 | 2019 | |
| Seqirus USA INC | $15.69 | 2022 | |
| Merck Sharp & Dohme LLC | $15.00 | 2025 | Gardasil 9, Capvaxive |
| Boston Scientific Corporation | $14.68 | 2023 | Watchman Access System |
| Novartis Pharmaceuticals Corporation | $13.26 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $11.44 | 2019 | |
| Strongbridge US INC. | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.